vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and First Seacoast Bancorp, Inc. (FSEA). Click either name above to swap in a different company.

Arcturus Therapeutics Holdings Inc. is the larger business by last-quarter revenue ($7.2M vs $4.0M, roughly 1.8× First Seacoast Bancorp, Inc.). On growth, First Seacoast Bancorp, Inc. posted the faster year-over-year revenue change (20.6% vs -68.4%). First Seacoast Bancorp, Inc. produced more free cash flow last quarter ($329.0K vs $-74.5M). Over the past eight quarters, First Seacoast Bancorp, Inc.'s revenue compounded faster (12.6% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

Sterling Bancorp was an American regional bank holding company that owned Sterling National Bank. It merged into Webster Bank in February 2022.

ARCT vs FSEA — Head-to-Head

Bigger by revenue
ARCT
ARCT
1.8× larger
ARCT
$7.2M
$4.0M
FSEA
Growing faster (revenue YoY)
FSEA
FSEA
+88.9% gap
FSEA
20.6%
-68.4%
ARCT
More free cash flow
FSEA
FSEA
$74.8M more FCF
FSEA
$329.0K
$-74.5M
ARCT
Faster 2-yr revenue CAGR
FSEA
FSEA
Annualised
FSEA
12.6%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARCT
ARCT
FSEA
FSEA
Revenue
$7.2M
$4.0M
Net Profit
$-87.0K
Gross Margin
Operating Margin
-3.1%
Net Margin
-2.4%
Revenue YoY
-68.4%
20.6%
Net Profit YoY
3.1%
93.8%
EPS (diluted)
$-0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
FSEA
FSEA
Q4 25
$7.2M
$4.0M
Q3 25
$17.2M
$4.0M
Q2 25
$28.3M
$3.9M
Q1 25
$29.4M
$3.5M
Q4 24
$22.8M
$3.4M
Q3 24
$41.7M
$3.3M
Q2 24
$49.9M
$5.9M
Q1 24
$38.0M
$3.2M
Net Profit
ARCT
ARCT
FSEA
FSEA
Q4 25
$-87.0K
Q3 25
$-13.4M
$390.0K
Q2 25
$-9.2M
$-545.0K
Q1 25
$-14.1M
$-603.0K
Q4 24
$-30.0M
$-1.4M
Q3 24
$-6.9M
$44.0K
Q2 24
$-17.2M
$2.0M
Q1 24
$-26.8M
$-1.2M
Operating Margin
ARCT
ARCT
FSEA
FSEA
Q4 25
-3.1%
Q3 25
-96.3%
-5.2%
Q2 25
-41.0%
-13.7%
Q1 25
-57.3%
-17.9%
Q4 24
-146.7%
-23.5%
Q3 24
-25.8%
-17.8%
Q2 24
-42.4%
35.6%
Q1 24
-80.0%
-24.8%
Net Margin
ARCT
ARCT
FSEA
FSEA
Q4 25
-2.4%
Q3 25
-78.4%
9.8%
Q2 25
-32.4%
-14.1%
Q1 25
-47.9%
-17.1%
Q4 24
-131.8%
-46.9%
Q3 24
-16.6%
1.3%
Q2 24
-34.5%
33.9%
Q1 24
-70.5%
-36.1%
EPS (diluted)
ARCT
ARCT
FSEA
FSEA
Q4 25
$-0.04
Q3 25
$-0.49
$0.08
Q2 25
$-0.34
$-0.13
Q1 25
$-0.52
$-0.14
Q4 24
$-1.10
$-0.31
Q3 24
$-0.26
$0.01
Q2 24
$-0.64
$0.42
Q1 24
$-1.00
$-0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
FSEA
FSEA
Cash + ST InvestmentsLiquidity on hand
$230.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$214.0M
$63.5M
Total Assets
$271.1M
$599.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
FSEA
FSEA
Q4 25
$230.9M
Q3 25
$180.4M
Q2 25
$196.5M
Q1 25
$216.9M
Q4 24
$237.0M
Q3 24
$237.2M
Q2 24
$260.3M
Q1 24
$288.4M
Stockholders' Equity
ARCT
ARCT
FSEA
FSEA
Q4 25
$214.0M
$63.5M
Q3 25
$224.6M
$63.2M
Q2 25
$231.1M
$60.8M
Q1 25
$233.8M
$61.2M
Q4 24
$241.0M
$62.0M
Q3 24
$261.9M
$65.8M
Q2 24
$258.6M
$64.5M
Q1 24
$264.0M
$64.7M
Total Assets
ARCT
ARCT
FSEA
FSEA
Q4 25
$271.1M
$599.3M
Q3 25
$282.3M
$609.6M
Q2 25
$309.3M
$604.8M
Q1 25
$331.8M
$592.6M
Q4 24
$344.1M
$580.8M
Q3 24
$370.7M
$601.8M
Q2 24
$388.6M
$601.7M
Q1 24
$418.8M
$576.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
FSEA
FSEA
Operating Cash FlowLast quarter
$-74.3M
$449.0K
Free Cash FlowOCF − Capex
$-74.5M
$329.0K
FCF MarginFCF / Revenue
-1035.2%
8.1%
Capex IntensityCapex / Revenue
3.2%
3.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
FSEA
FSEA
Q4 25
$-74.3M
$449.0K
Q3 25
$-17.2M
$661.0K
Q2 25
$-5.8M
$-151.0K
Q1 25
$-35.1M
$573.0K
Q4 24
$-284.0K
$-2.9M
Q3 24
$-23.8M
$289.0K
Q2 24
$-30.1M
$-1.4M
Q1 24
$-5.6M
$-70.0K
Free Cash Flow
ARCT
ARCT
FSEA
FSEA
Q4 25
$-74.5M
$329.0K
Q3 25
$-17.3M
$640.0K
Q2 25
$-154.0K
Q1 25
$-35.3M
$542.0K
Q4 24
$-3.3M
Q3 24
$-23.8M
$264.0K
Q2 24
$-30.5M
$-1.6M
Q1 24
$-5.8M
$-81.0K
FCF Margin
ARCT
ARCT
FSEA
FSEA
Q4 25
-1035.2%
8.1%
Q3 25
-101.1%
16.0%
Q2 25
-4.0%
Q1 25
-120.1%
15.4%
Q4 24
-99.0%
Q3 24
-57.2%
7.9%
Q2 24
-61.1%
-26.5%
Q1 24
-15.3%
-2.5%
Capex Intensity
ARCT
ARCT
FSEA
FSEA
Q4 25
3.2%
3.0%
Q3 25
1.1%
0.5%
Q2 25
0.0%
0.1%
Q1 25
0.5%
0.9%
Q4 24
0.0%
11.0%
Q3 24
0.2%
0.7%
Q2 24
0.7%
2.8%
Q1 24
0.6%
0.3%
Cash Conversion
ARCT
ARCT
FSEA
FSEA
Q4 25
Q3 25
1.69×
Q2 25
Q1 25
Q4 24
Q3 24
6.57×
Q2 24
-0.70×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons